All In Biotech

BLA 761051 · Kyowa Kirin

Poteligeo

Mogamulizumab-Kpkc · Injection · Chemokine Receptor Type 4 Interaction; Monoclonal Antibody

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Feb 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Aug 8, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

36

2 Phase 3, 8 recruiting

FAERS reports

1,361

819 serious, 198 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 2, 2026.

POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. POTELIGEO is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy ( 1 ).

Mechanism: Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs. Non-clinical in vitro studies demonstrate mogamulizumab-kpkc binding targets a cell for antibody-dependent cellular cytotoxicity (ADCC) resulting in depletion of the target cells. CCR4 is expressed on the surface of some T-cell malignancies and is expressed on regulatory T-cells (Treg) and a subset of Th2 T-cells.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 8, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • POTELIGEO · MOGAMULIZUMAB-KPKC 20MG/5ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mogamulizumab" as an intervention, any sponsor and status, largest first.

All 36 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • rash193
  • disease progression123
  • drug eruption81
  • pruritus68
  • infusion related reaction59
  • death55
  • pyrexia52
  • fatigue49
  • inappropriate schedule of product administration42
  • chills41
  • drug ineffective37
  • erythema36

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
20131
20142
20152
20163
20173
201822
2019210
2020179
2021223
2022227
2023109
2024134
2025125
2026120

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Poteligeo (Mogamulizumab-Kpkc)

2024 spending

$1.8M

Beneficiaries

12

41 claims

Per beneficiary

$153,518

$914.25 per unit

View as table
YearSpending
2020$629,052
2021$1,449,396
2022$1,261,538
2023$1,906,447
2024$1,842,214

Part B: Poteligeo (Mogamulizumab-Kpkc) · HCPCS J9204

2024 spending

$76.3M

Beneficiaries

344

3,771 claims

Per beneficiary

$221,874

2024 ASP limit $236.43 per unit

View as table
YearSpending
2020$42,735,536
2021$52,270,180
2022$60,408,204
2023$62,069,663
2024$76,324,768

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 47 on PubMed

Sponsor: Kyowa Kirin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.